Oppenheimer Comments On ImmunoGen 4Q11 Results

According to Oppenheimer, ImmunoGen IMGN reported 4QFY11 results. Oppenheimer said that Roche reported a statistically significant PFS benefit in top-line results. “We see near-term upside for IMGN on the T-DM1 results at ESMO, and we expect growing recognition of the value of the company's TAP technology to underpin shares.” ImmunoGen closed yesterday at $12.33.